Research Letter

Sorafenib-Induced Acute Generalized Exanthematous Pustulosis

Author Affiliation(s)



1. Sidoroff A, Halevy S, Bavinck JN, Vaillant L, Roujeau JC. Acute generalized exanthematous pustulosis (AGEP): a clinical reaction pattern. J Cutan Pathol. 2001;28(3):113-119. DOI: 10.1034/j.1600-0560.2001.028003113.x. PMID: 11168761. 2. Sidoroff A, Dunant A, Viboud C, et al. Risk factors for acute generalized exanthematous pustulosis (AGEP)-results of a multinational case-control study (EuroSCAR). Br J Dermatol. 2007;157(5):989-996. DOI: 10.1111/j.1365-2133.2007.08156.x. PMID: 17854366. 3. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239-245. DOI: 10.1038/clpt.1981.154. PMID: 7249508. 4. Bracarda S, Ruggeri EM, Monti M, et al. Early detection, prevention and management of cutaneous adverse events due to sorafenib: recommendations from the Sorafenib Working Group. Crit Rev Oncol Hematol. 2012;82(3):378-386. DOI: 10.1016/j.critrevonc.2011.08.005. PMID: 21944842. 5. Liang CP, Yang CS, Shen JL, Chen YJ. Sorafenib-induced acute localized exanthematous pustulosis in a patient with hepatocellular carcinoma. Br J Dermatol. 2011;165(2):443-445. DOI: 10.1111/j.1365-2133.2011.10377.x. PMID: 21495998. 6. Pretel M, Iñarrairaegui M, Lera JM, Aguado L, Idoate MA. Acute generalized exanthematous pustulosis induced by sorafenib. JAMA Dermatol. 2014;150(6):664-666. DOI: 10.1001/jamadermatol.2013.6924. PMID: 24671701. 7. Alegre-Sánchez A, de Perosanz-Lobo D, Pinilla-Pagnon I, Muñoz-Zato E. Sorafenib-induced Acute Generalized Exanthematous Pustulosis: An Increasing Association? Actas Dermosifiliogr. 2017;108(6):599-601. DOI: 10.1016/ PMID: 28262110.

Send mail to Author

Send Cancel